Multiple Sclerosis Care Springfield Lakes: Comprehensive MS Treatment 2025

Living with multiple sclerosis? MS affects 25,600 Australians, making it the most common neurological disease in young adults. With early diagnosis and modern treatments, many people with MS can live full, productive lives.

Understanding Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system where the immune system attacks myelin, the protective sheath around nerve fibers, causing inflammation, demyelination, and neurodegeneration.

Types of Multiple Sclerosis

Type	Characteristics	Prevalence	Prognosis
Relapsing-Remitting (RRMS)	Distinct attacks, complete recovery	85% at onset	Variable progression
Secondary Progressive (SPMS)	Initial RR, then steady progression	50% after 10-15 years	Gradual worsening
Primary Progressive (PPMS)	Steady progression from onset	10-15%	Continuous decline
Progressive-Relapsing (PRMS)	Progressive with acute relapses	5%	Poor prognosis

Clinical Course Patterns

Clinically isolated syndrome (CIS) – first neurological episode
Radiologically isolated syndrome (RIS) – MRI findings without symptoms
Benign MS – minimal disability after 15+ years
Malignant MS – rapid progression, severe disability

Pathophysiology

Autoimmune inflammation – T-cell mediated immune response
Demyelination – loss of myelin sheath
Axonal damage – nerve fiber injury and loss
Remyelination – partial repair attempts
Neurodegeneration – progressive brain and spinal cord atrophy

Symptoms and Clinical Presentation

Common Initial Symptoms

Optic neuritis – vision loss, eye pain (25% of cases)
Sensory symptoms – numbness, tingling, burning
Motor weakness – limb weakness, fatigue
Coordination problems – balance, tremor, ataxia
Cognitive symptoms – memory, concentration difficulties

Symptom Categories

Motor Symptoms:

Weakness – limbs, trunk muscles
Spasticity – muscle stiffness, spasms
Tremor – action or intention tremor
Coordination problems – ataxia, dysmetria
Walking difficulties – gait abnormalities

Sensory Symptoms:

Numbness – face, limbs, trunk
Tingling – pins and needles sensation
Burning pain – neuropathic pain
Loss of position sense – proprioception
Lhermitte’s sign – electric shock sensation

Visual Symptoms:

Optic neuritis – pain, vision loss
Double vision – diplopia from brainstem lesions
Nystagmus – involuntary eye movements
Visual field defects – partial vision loss

Cognitive and Emotional Symptoms:

Memory problems – short-term memory loss
Processing speed – slowed thinking
Executive dysfunction – planning, problem-solving
Depression – 50% lifetime prevalence
Anxiety – worry about disease progression

Other Symptoms:

Fatigue – overwhelming tiredness (80% of patients)
Bladder dysfunction – urgency, frequency, retention
Bowel problems – constipation, incontinence
Sexual dysfunction – decreased libido, erectile dysfunction
Speech problems – dysarthria, scanning speech

Diagnosis and Assessment

Diagnostic Criteria (2017 McDonald Criteria)

Clinical attacks – objective neurological symptoms
MRI lesions – dissemination in space and time
CSF analysis – oligoclonal bands, IgG index
Differential diagnosis – exclude other conditions

Required Evidence

Evidence Type	Requirements	Methods
Dissemination in Space	≥2 CNS areas affected	Clinical + MRI
Dissemination in Time	≥2 attacks or MRI changes	Clinical history + MRI
No Better Explanation	Rule out mimics	Comprehensive evaluation

Diagnostic Tests

MRI Brain and Spinal Cord:

T2-weighted lesions – white matter hyperintensities
Gadolinium enhancement – active inflammation
Black holes – T1 hypointense lesions
Brain atrophy – tissue loss measurement

Cerebrospinal Fluid Analysis:

Oligoclonal bands – present in 95% of MS patients
IgG index – elevated intrathecal synthesis
Cell count – mild lymphocytic pleocytosis
Protein levels – normal to mildly elevated

Evoked Potentials:

Visual evoked potentials – optic nerve function
Brainstem auditory – auditory pathway assessment
Somatosensory – sensory pathway evaluation
Motor evoked potentials – corticospinal tract function

Differential Diagnosis

Neuromyelitis optica – anti-AQP4 antibodies
Acute disseminated encephalomyelitis – monophasic illness
Systemic lupus erythematosus – ANA, anti-dsDNA positive
Behcet’s disease – oral/genital ulcers
Sarcoidosis – pulmonary involvement, ACE levels
Vitamin B12 deficiency – subacute combined degeneration

Treatment Approaches

Disease-Modifying Therapies (DMTs)

First-Line Injectable Therapies:

Medication	Route	Frequency	Efficacy
Interferon β-1a	IM	Weekly	30% relapse reduction
Interferon β-1a	SC	3x weekly	32% relapse reduction
Interferon β-1b	SC	Every other day	34% relapse reduction
Glatiramer acetate	SC	Daily	29% relapse reduction

Oral Therapies:

Dimethyl fumarate – twice daily, 44-53% relapse reduction
Teriflunomide – once daily, 31% relapse reduction
Fingolimod – once daily, 54% relapse reduction
Siponimod – once daily, for SPMS
Ozanimod – once daily, S1P receptor modulator

High-Efficacy Therapies:

Natalizumab – IV monthly, 68% relapse reduction
Ocrelizumab – IV every 6 months, 46-47% relapse reduction
Alemtuzumab – IV yearly x2, 49-55% relapse reduction
Cladribine – oral, short courses, 58% relapse reduction

Treatment Selection Principles

Risk-benefit assessment – efficacy vs. side effects
Disease activity – relapse rate, MRI lesions
Patient factors – age, pregnancy plans, comorbidities
Monitoring requirements – safety laboratory tests
Escalation strategy – start with safer agents

Symptomatic Treatments

Fatigue Management:

Amantadine – 100mg twice daily
Modafinil – 100-200mg daily
Energy conservation – pacing, rest periods
Exercise programs – aerobic, resistance training
Sleep hygiene – adequate rest, sleep disorders treatment

Spasticity Treatment:

Baclofen – oral or intrathecal pump
Tizanidine – muscle relaxant
Gabapentin – neuropathic pain and spasticity
Botulinum toxin – focal spasticity
Physical therapy – stretching, strengthening

Bladder Dysfunction:

Anticholinergics – oxybutynin, tolterodine
Beta-3 agonists – mirabegron
Intermittent catheterization – for retention
Bladder training – behavioral techniques
Urological evaluation – complex cases

Relapse Management

Defining a Relapse

Duration – symptoms lasting ≥24 hours
Timing – ≥30 days since previous relapse
Absence of fever – not infection-related
New neurological symptoms – or worsening of previous

Acute Treatment

IV methylprednisolone – 1g daily x 3-5 days
Oral prednisolone – high dose alternative
Plasma exchange – for severe, steroid-unresponsive relapses
Supportive care – symptom management
Rehabilitation – early mobilization

Recovery Patterns

Complete recovery – return to baseline (40% of relapses)
Partial recovery – some residual deficits (40%)
No recovery – persistent new deficits (20%)
Recovery time – weeks to months

Progressive MS Management

Primary Progressive MS (PPMS)

Ocrelizumab – only approved DMT for PPMS
Symptomatic treatment – spasticity, pain, fatigue
Rehabilitation – maintain function, prevent complications
Assistive devices – mobility aids, adaptive equipment
Multidisciplinary care – coordinated team approach

Secondary Progressive MS (SPMS)

Siponimod – for active SPMS
Mitoxantrone – limited use due to cardiotoxicity
Off-label DMTs – continued if active inflammation
Symptom management – quality of life focus
Disability prevention – falls, pressure sores

Monitoring and Follow-up

Regular Assessments

Clinical evaluation – neurological examination, EDSS scoring
MRI monitoring – annual brain, spinal cord if indicated
Laboratory monitoring – DMT-specific safety parameters
Functional assessment – walking, cognition, quality of life
Vaccination status – especially if on immunosuppressive therapy

Disability Scoring

Expanded Disability Status Scale (EDSS):

0.0-3.0 – Mild disability, fully ambulatory
3.5-5.5 – Moderate disability, walking limitations
6.0-7.5 – Severe disability, assistance required
8.0-9.5 – Restricted to bed/chair
10.0 – Death due to MS

Treatment Monitoring

Parameter	Frequency	Purpose
Clinical assessment	Every 3-6 months	Disease activity, side effects
MRI brain	Annually	New lesions, atrophy
Blood tests	Variable by DMT	Safety monitoring
Liver function	DMT-specific	Hepatotoxicity screening
Blood counts	DMT-specific	Bone marrow suppression

Pregnancy and MS

Pregnancy Planning

Preconception counseling – DMT discontinuation timing
Folic acid supplementation – 5mg daily
DMT safety – pregnancy category assessment
Genetic counseling – MS risk in offspring (2-5%)

Pregnancy Effects on MS

Relapse rate – decreases during pregnancy (especially 3rd trimester)
Postpartum period – increased relapse risk (3-6 months)
Long-term disability – no impact on overall progression
Breastfeeding – may reduce postpartum relapses

Safe Medications During Pregnancy

Corticosteroids – safe for relapses
Glatiramer acetate – can continue if needed
Interferon β – limited data, generally avoided
Symptomatic treatments – case-by-case assessment

Living with MS

Lifestyle Modifications

Regular exercise – aerobic, resistance, flexibility training
Healthy diet – Mediterranean diet, vitamin D supplementation
Stress management – relaxation techniques, counseling
Temperature avoidance – heat sensitivity management
Energy conservation – pacing activities, rest periods

Workplace Accommodations

Flexible scheduling – accommodate fatigue patterns
Ergonomic adjustments – proper seating, lighting
Technology aids – voice recognition, memory aids
Temperature control – air conditioning, cooling devices
Disability support – occupational rehabilitation services

Home Modifications

Accessibility – ramps, widened doorways
Bathroom safety – grab bars, shower chairs
Kitchen adaptations – reachable storage, ergonomic tools
Mobility aids – walkers, wheelchairs, scooters
Emergency planning – medical alert systems

Complications and Prognosis

Long-term Complications

Progressive disability – mobility, cognitive impairment
Secondary complications – falls, fractures, pressure sores
Medication side effects – infection risk, liver toxicity
Psychological impact – depression, anxiety, adjustment disorders
Social consequences – employment, relationships, independence

Prognostic Factors

Good Prognosis:

Female gender – better long-term outcomes
Younger onset age – <40 years
Relapsing-remitting course – vs. progressive
Complete recovery – from early relapses
Low lesion load – on initial MRI

Poor Prognosis:

Male gender – more aggressive course
Older onset age – >40 years
Progressive course – from onset
Incomplete recovery – residual deficits
High lesion load – extensive MRI changes

Life Expectancy

Reduced by 6-7 years – compared to general population
Cause of death – MS-related complications (50%)
Suicide risk – 2-3 times higher than general population
Infections – respiratory complications

Emergency Situations

MS Emergencies

Severe relapse – transverse myelitis, brainstem symptoms
Fulminant MS – rapidly progressive, severe disability
Treatment complications – PML, severe infections
Psychiatric crisis – severe depression, suicidal ideation
Status epilepticus – rare but possible

When to Seek Immediate Care

New severe neurological symptoms – weakness, vision loss
Signs of infection – fever with immunosuppressive therapy
Severe depression – suicidal thoughts
Medication reactions – allergic reactions, liver toxicity
Breathing difficulties – respiratory muscle weakness

Take Action: MS Care Support

Living with MS requires expert care and comprehensive support. Health Hub Springfield Lakes provides specialized multiple sclerosis management and treatment.

Book Your MS Consultation

Online booking: Available 24/7 at healthhubspringfieldlakes.com.au/
Phone booking: Call +61 7 3778 4888
Comprehensive evaluation: Neurological assessment and MRI coordination
Treatment planning: Personalized MS management strategies

Address: 18 Springfield Lakes Blvd, Springfield Lakes QLD 4300
Your trusted partner for comprehensive MS care and neurological wellness.

Medical References

Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.
Multiple Sclerosis Society of Australia. Economic Impact of Multiple Sclerosis in Australia in 2017. Sydney: MS Australia; 2018.
Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96-120.
Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777-788.
Australian Government Department of Health. Medicare Benefits Schedule: Multiple sclerosis services. Canberra: Commonwealth of Australia; 2021.
Therapeutic Guidelines Limited. Neurology: Multiple sclerosis. In: eTG complete. Melbourne: Therapeutic Guidelines Limited; 2021.
National Multiple Sclerosis Society. Disease-modifying therapies for MS. Available from: https://www.nationalmssociety.org/
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. 9th ed. Melbourne: RACGP; 2018.
Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord. 2016;9(3):198-210.

Medical Disclaimer: This information is for educational purposes and does not replace professional medical advice. If you’re experiencing symptoms of multiple sclerosis or have been diagnosed with MS, please consult a healthcare professional promptly. Health Hub Springfield Lake’s medical team provides comprehensive multiple sclerosis care and support.